HemaCare Co. (OTCMKTS:HEMA – Get Free Report)’s share price traded up 0.6% on Thursday . The stock traded as high as $25.31 and last traded at $25.31. 5,400 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 39,950 shares. The stock had previously closed at $25.16.
HemaCare Stock Performance
The firm has a 50 day simple moving average of $25.31 and a 200-day simple moving average of $25.31.
HemaCare Company Profile
HemaCare Corporation is a specialty life sciences company that supplies primary human blood and bone marrow-derived cells for research, drug development and medical device evaluation. The company’s product portfolio includes peripheral blood mononuclear cells (PBMCs), buffy coats, hematopoietic stem and progenitor cells, whole blood, bone marrow aspirates and custom-processed cell fractions. These offerings are designed to support preclinical studies, translational research and in vitro assays across immunology, hematology, oncology and regenerative medicine applications.
In addition to off-the-shelf cell products, HemaCare provides custom cell isolation services, donor screening and logistics solutions tailored to the needs of pharmaceutical, biotechnology and academic customers.
Recommended Stories
- Five stocks we like better than HemaCare
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for HemaCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HemaCare and related companies with MarketBeat.com's FREE daily email newsletter.
